

Patrick M Moriarty

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/569186/publications.pdf>

Version: 2024-02-01

63
papers

4,091
citations

185998

28
h-index

133063

59
g-index

65
all docs

65
docs citations

65
times ranked

4031
citing authors

#	ARTICLE	IF	CITATIONS
1	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. <i>European Heart Journal</i> , 2022, 43, 1401-1412.	1.0	78
2	Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study. <i>Atherosclerosis</i> , 2022, 341, 43-49.	0.4	28
3	Effectiveness of a Novel 3-Krill Oil Agent in Patients With Severe Hypertriglyceridemia. <i>JAMA Network Open</i> , 2022, 5, e2141898.	2.8	14
4	Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. <i>American Heart Journal</i> , 2021, 235, 104-112.	1.2	82
5	Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a). <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 159-173.	1.2	22
6	Establishing low-density lipoprotein apheresis tolerability in patients with prior anaphylactoid reactions to lipoprotein apheresis using magnesium sulfate. <i>Journal of Clinical Apheresis</i> , 2021, 36, 437-442.	0.7	1
7	Emerging RNA Therapeutics to Lower Blood Levels of Lp(a). <i>Journal of the American College of Cardiology</i> , 2021, 77, 1576-1589.	1.2	86
8	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 264-275.	5.5	109
9	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 133-144.	1.2	296
10	A retrospective analysis of clinical use of alirocumab in lipoprotein apheresis patients. <i>Journal of Clinical Lipidology</i> , 2020, 14, 818-824.	0.6	3
11	Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis. <i>Current Atherosclerosis Reports</i> , 2020, 22, 48.	2.0	55
12	Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. <i>Journal of Clinical Lipidology</i> , 2020, 14, 88-97.e2.	0.6	12
13	Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5253-5262.	1.8	4
14	Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 901-909.e3.	0.6	14
15	Pseudohypertriglyceridemia—Raising clinical awareness. <i>Journal of Clinical Lipidology</i> , 2019, 13, 855-856.	0.6	0
16	Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. <i>Atherosclerosis</i> , 2019, 289, 85-93.	0.4	60
17	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 1578-1589.	1.6	34
18	Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2019, 13, 894-900.	0.6	44

#	ARTICLE	IF	CITATIONS
19	Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. <i>Journal of the Endocrine Society</i> , 2019, 3, 2397-2410.	0.1	32
20	Comparing patients' prescribed, self-reported, and actual intake of supplemental eicosapentaenoic acid + docosahexaenoic acid. <i>Journal of Clinical Lipidology</i> , 2019, 13, 170-175.	0.6	1
21	Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019, 280, 109-117.	0.4	40
22	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 177-192.	1.2	337
23	Variability in Potency Among Commercial Preparations of Berberine. <i>Journal of Dietary Supplements</i> , 2018, 15, 343-351.	1.4	10
24	Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1358-1366.	0.6	30
25	Therapeutic plasma exchange for the treatment of systemic sclerosis: A comprehensive review and analysis. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 132-152.	1.0	15
26	The Role of Nutraceuticals in Statin Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018, 72, 96-118.	1.2	216
27	Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 580-588.	1.1	76
28	Successful long-term (22 year) treatment of limited scleroderma using therapeutic plasma exchange: Is blood rheology the key?. <i>Clinical Hemorheology and Microcirculation</i> , 2017, 65, 131-136.	0.9	4
29	Toward an international consensus: Integrating lipoprotein apheresis and new lipid-lowering drugs. <i>Journal of Clinical Lipidology</i> , 2017, 11, 858-871.e3.	0.6	105
30	Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. <i>Current Cardiology Reports</i> , 2017, 19, 62.	1.3	3
31	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry. <i>Atherosclerosis</i> , 2017, 267, 19-26.	0.4	64
32	Case report of male child with elevated lipoprotein (a) leading to acute ischemic stroke. <i>Journal of Clinical Apheresis</i> , 2017, 32, 574-578.	0.7	7
33	Lipoprotein-X disease in the setting of severe cholestatic hepatobiliary autoimmune disease. <i>Journal of Clinical Lipidology</i> , 2017, 11, 282-286.	0.6	11
34	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1290-1301.	1.2	162
35	Lipoprotein apheresis reduces circulating galectin-3 in humans. <i>Journal of Clinical Apheresis</i> , 2016, 31, 388-392.	0.7	11
36	JCL Roundtable: Should we treat elevations in Lp(a)? <i>Journal of Clinical Lipidology</i> , 2016, 10, 215-224.	0.6	8

#	ARTICLE	IF	CITATIONS
37	Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. <i>European Heart Journal</i> , 2016, 37, 3588-3595.	1.0	174
38	US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1223-1229.	0.6	57
39	A phase III randomized trial evaluating alirocumab 300Âmg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. <i>Atherosclerosis</i> , 2016, 254, 254-262.	0.4	91
40	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. <i>Lancet Diabetes and Endocrinology</i> ,the, 2016, 4, 850-861.	5.5	329
41	Lipoprotein Apheresis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, 39-54.	1.2	22
42	JCL roundtable: PCSK9 inhibitors in clinical practice. <i>Journal of Clinical Lipidology</i> , 2016, 10, 5-14.	0.6	6
43	Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial. <i>Journal of Clinical Lipidology</i> , 2016, 10, 627-634.	0.6	17
44	Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. <i>Journal of Clinical Lipidology</i> , 2015, 9, 758-769.	0.6	390
45	Welcome to the 10thCongress of the International Society for Apheresis. <i>Therapeutic Apheresis and Dialysis</i> , 2015, 19, 101-102.	0.4	0
46	Lipoprotein apheresis. <i>Current Opinion in Lipidology</i> , 2015, 26, 544-552.	1.2	21
47	Statins and almonds to lower lipoproteins (the STALL Study). <i>Journal of Clinical Lipidology</i> , 2015, 9, 58-64.	0.6	31
48	Lipoprotein Apheresis. <i>Cardiology Clinics</i> , 2015, 33, 197-208.	0.9	25
49	Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. <i>Journal of Clinical Lipidology</i> , 2014, 8, 554-561.	0.6	128
50	Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry. <i>American Heart Journal</i> , 2014, 167, 342-349.e17.	1.2	76
51	Apple pectin for the reduction of niacin-induced flushing. <i>Journal of Clinical Lipidology</i> , 2013, 7, 140-146.	0.6	7
52	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. <i>Journal of Clinical Lipidology</i> , 2011, 5, 133-140.	0.6	483
53	Effect of Low-Density Lipoprotein Apheresis on Plasma Levels of Apolipoprotein E4. <i>American Journal of Cardiology</i> , 2010, 105, 1585-1587.	0.7	13
54	Supratherapeutic Response to Ezetimibe in a Statin Intolerant Patient. <i>Hospital Pharmacy</i> , 2010, 45, 45-48.	0.4	0

#	ARTICLE	IF	CITATIONS
55	LDL-apheresis therapy. Current Treatment Options in Cardiovascular Medicine, 2006, 8, 282-288.	0.4	24
56	Association between hematological parameters and high-density lipoprotein cholesterol. Current Opinion in Cardiology, 2005, 20, 318-323.	0.8	21
57	Effect of Low-Density Lipoprotein Apheresis on Lipoprotein-Associated Phospholipase A2. American Journal of Cardiology, 2005, 95, 1246-1247.	0.7	21
58	Treatment of acute occlusion of the retinal artery by LDL-apheresis. Journal of Clinical Apheresis, 2005, 20, 88-92.	0.7	6
59	Effect of low-density lipoprotein cholesterol apheresis on blood viscosity. American Journal of Cardiology, 2004, 93, 1044-1046.	0.7	40
60	Pulse Pressure and Risk of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2003, 289, 174.	3.8	0
61	The Effect of Micronized Fenofibrate on Lipid Profiles of Patients Converted from Gemfibrozil. Hospital Pharmacy, 2002, 37, 953-956.	0.4	1
62	Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses. Current Atherosclerosis Reports, 2001, 3, 156-162.	2.0	8
63	Using both "relative risk reduction" and "number needed to treat" in evaluating primary and secondary clinical trials of lipid reduction. American Journal of Cardiology, 2001, 87, 1206-1208.	0.7	10